<DOC>
	<DOCNO>NCT02517528</DOCNO>
	<brief_summary>This Phase 3 , open-label , multicenter study evaluate efficacy safety ABT 450/r/ ABT 267 ABT-333 coadministered ribavirin ( RBV ) 12 week HCV genotype 1b , treatment naïve Interferon ( IFN ) ( alpha , beta pegIFN ) plus RBV treatment-experienced Asian adult compensate cirrhosis .</brief_summary>
	<brief_title>ABT-450/Ritonavir/ ABT 267 ( ABT-450/r/ABT-267 ) ABT -333 Co-administered With Ribavirin ( RBV ) Treatment Naïve Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus ( HCV ) Infection Compensated Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>1 . Chinese , South Korean , Taiwanese descent full Chinese , South Korean , Taiwanese parentage . 2 . Chronic HCVinfection prior study enrollment . 3 . Screening laboratory result indicate HCV genotype 1binfection . 4 . Compensated cirrhosis define ChildPugh Score less equal 6 Screening . 5 . Per local standard practice , documentation cirrhosis one follow method : Diagnosis previous liver biopsy liver biopsy conduct screen e.g. , Metavir Score &gt; 3 ( include 3/4 3 4 ) , Ishak score &gt; 4 , FibroScan score ≥ 14.6 kPa within 6 month Screening Screening Period . 1 . HCV genotype perform screen indicate unable genotype infection HCV genotype . 2 . Positive test result Screening Hepatitis B surface antigen ( HBsAg ) , HBV DNA &gt; Lower Limit Quantification ( LLOQ ) HBsAg negative , antiHuman Immunodeficiency virus antibody ( HIV Ab ) . 3 . Use know strong inducer cytochrome P450 3A ( CYP3A ) strong inhibitor CYP2C8 within 2 week within 10 halflives , whichever longer , respective medication/supplement prior study drug administration . 4 . Any current past clinical evidence ChildPugh B C classification clinical history liver decompensation include ascites ( noted physical exam ) , variceal bleeding , hepatic encephalopathy . 5 . Serum AlphaFetoprotein ( sAFP ) &gt; 100 ng/mL Screening . 6 . Confirmed presence hepatocellular carcinoma ( HCC ) indicate image technique compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) within 3 month prior Screening ultrasound perform Screening ( positive ultrasound result confirm CT scan MRI . ) 7 . Any primary cause liver disease chronic HCVinfection , include limited following : Hemochromatosis Alpha1 antitrypsin deficiency Wilson 's disease Autoimmune hepatitis Alcoholic liver disease Drugrelated liver disease Steatosis steatohepatitis liver biopsy coincident HCVrelated change would consider exclusionary unless steatohepatitis consider primary cause liver disease . 8 . Screening laboratory analysis show abnormal kidney , hepatic , hematologic function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>( HCV ) Infection</keyword>
	<keyword>Compensated Cirrhosis</keyword>
</DOC>